US own-label revenue
₹100 crore
+100% YoY (first full year)
Own-label business reached ~₹100 crore in first full year; target to double to ~₹200 crore next year.
CAPLINPOINTLABORATORIES
Other
15 May 2026
Caplin Point Laboratories Ltd — Q4 FY26
Caplin Point delivered a strong FY26 with revenue doubling over five years to ₹2,300 crore and liquid assets tripling to ₹2,726 crore.
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Caplin Point delivered a strong FY26 with revenue doubling over five years to ₹2,300 crore and liquid assets tripling to ₹2,726 crore. PAT grew 20% ahead of revenue growth of 13%, reflecting operating leverage. The US subsidiary (CSL) posted EBITDA margins of 30% for FY26, with own-label revenue nearing ₹100 crore in its first full year. Management guided for 25-30% growth in CSL next year and aims to double own-label sales to ~₹200 crore. Key drivers include 17 injectable lines coming online over 2-3 years, expansion in Latin America (Chile, Mexico), and a strong pipeline of 60 ANDAs. Risks include execution delays in capacity expansion and potential margin pressure from input cost inflation, though management believes its anti-fragile inventory model mitigates disruptions.
कैप्लिन पॉइंट ने वित्त वर्ष 2026 में शानदार प्रदर्शन किया। पिछले पांच सालों में कंपनी की कमाई दोगुनी होकर ₹2,300 करोड़ हो गई, और नकद संपत्ति तीन गुना बढ़कर ₹2,726 करोड़ पहुंच गई। मुनाफा (PAT) 20% बढ़ा, जो कमाई की 13% बढ़ोतरी से ज्यादा है - इसका मतलब कंपनी ने लागत पर अच्छा नियंत्रण रखा। अमेरिकी सहायक कंपनी (CSL) ने 30% का मुनाफा मार्जिन हासिल किया, और अपने ब्रांड की बिक्री पहले साल में ₹100 करोड़ के करीब पहुंच गई। अगले साल CSL में 25-30% और अपने ब्रांड की बिक्री ₹200 करोड़ तक बढ़ाने का लक्ष्य है। नए इंजेक्शन उत्पाद, लैटिन अमेरिका में विस्तार और 60 नई दवा अनुमतियां मुख्य कारण हैं। जोखिमों में उत्पादन में देरी और लागत बढ़ना शामिल है, लेकिन कंपनी का कहना है कि उसका मजबूत इन्वेंट्री मॉडल इसे संभाल लेगा।
Key Numbers
CSL EBITDA margin
30%
+200bps YoY
CSL EBITDA margin improved to 30% for FY26 from 27.97% in FY25.
ANDAs held
60
+25 YoY (10 approvals + 15 acquisitions)
Total ANDA count reached 60, with 10 approvals and 15 acquired in FY26.
Chile tender wins
$10 million
new
Won 35 products worth $10 million for supply over next 18 months in Chile.
Management Guidance
CSL overall growth 25-30% in FY27
Management expects the US subsidiary (CSL) to grow 25-30% in the coming year, driven by existing products and new launches.
Management guidance revenueOwn-label revenue target ~₹200 crore in FY27
Aim to double own-label revenue from ~₹100 crore to ~₹200 crore in the next fiscal year.
Management guidance revenueCapex of ~₹500 crore over next 18-24 months
Remaining capex of about ₹500 crore to be spent on injectable plant phase 3, oral solids/derma facility, and oncology API plant.
Management guidance capex17 injectable lines in 2-3 years
Company plans to have 17 injectable lines for US and regulated markets, with most machines imported from Germany and Italy.
Management guidance expansionKey Risks
Receivable days increase
Receivable days rose to ~136 days (11 days due to forex revaluation), partly from a large El Salvador tender. Management expects normalization by Q2 FY27.
medium · analyst_questionInput cost inflation from tariffs
US tariffs on Chinese APIs and raw materials could increase COGS. Management noted highest impact product saw <2% COGS increase, but broader escalation remains a risk.
medium · analyst_questionExecution risk in capacity expansion
Large capex program (₹500 crore residual) and new injectable lines may face delays or regulatory hurdles, impacting growth timelines.
medium · data_observationNotable Quotes
The best is yet to come maybe the best will come after two to three years.
We are not seeing a dearth of orders. In fact, we have an order book that's full for another 6 months almost.
Our anti-fragile model has really helped us for the best fundamentals even in rough markets of lifetime in the last five years.
Frequently Asked Questions
What was Caplin Point Laboratories's revenue in Q4 FY26?
Caplin Point Laboratories reported revenue of ₹600 Cr in Q4 FY26, representing a — change compared to the same quarter last year.
What guidance did Caplin Point Laboratories management give for FY27?
CSL overall growth 25-30% in FY27: Management expects the US subsidiary (CSL) to grow 25-30% in the coming year, driven by existing products and new launches. Own-label revenue target ~₹200 crore in FY27: Aim to double own-label revenue from ~₹100 crore to ~₹200 crore in the next fiscal year. Capex of ~₹500 crore over next 18-24 months: Remaining capex of about ₹500 crore to be spent on injectable plant phase 3, oral solids/derma facility, and oncology API plant. 17 injectable lines in 2-3 years: Company plans to have 17 injectable lines for US and regulated markets, with most machines imported from Germany and Italy.
What are the key risks for Caplin Point Laboratories in FY27?
Key risks include Receivable days increase — Receivable days rose to ~136 days (11 days due to forex revaluation), partly from a large El Salvador tender. Management expects normalization by Q2 FY27.; Input cost inflation from tariffs — US tariffs on Chinese APIs and raw materials could increase COGS. Management noted highest impact product saw <2% COGS increase, but broader escalation remains a risk.; Execution risk in capacity expansion — Large capex program (₹500 crore residual) and new injectable lines may face delays or regulatory hurdles, impacting growth timelines..
Did Caplin Point Laboratories meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Caplin Point Laboratories Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.